{'fraction_non_alphanumeric': 0.025830258302583026, 'fraction_numerical': 0.025830258302583026, 'mean_word_length': 5.1647727272727275, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Real‐world use of dupilumab for 53 patients with atopic dermatitis in Japan

Dear Editor, A single-center, retrospective chart review was conducted at Hyogo College of Medicine Hospital to assess the therapeutic effects and safety of dupilumab in patients with moderate-to-severe atopic dermatitis (AD) who visited the hospital from April 2018 to May 2019. Treatment began with a 600 mg loading dose of dupilumab, followed by a 300 mg dose, given every other week, combined with topical corticosteroids and/or tacrolimus, in accordance with Japanese National Health Insurance adaptation rules.1 This study conformed to the Declaration of Helsinki and was approved by the Ethics Review Board of Hyogo College of Medicine (approval number: 3273). Fifty-three Japanese patients (36 men and 17 women) were included. Disease activity was measured at the baseline visit and Weeks 4 and 16, with a window of assessment of approximately three days. The last observation carried forward method was used to impute missing values. The patients’ baseline clinical characteristics were as follows: